Affimed Announces Second Quarter 2018 Financial Results and Corporate Update Conference Call August 3, 2018
Affimed Announces Updated Data of AFM13 in Combination with Keytruda® (Pembrolizumab) in Patients with Relapsed/Refractory Hodgkin Lymphoma Presented at EHA June 15, 2018
Affimed Announces First Quarter 2018 Financial Results and Corporate Update Conference Call May 8, 2018
Affimed Presents Poster at AACR Highlighting Progress Toward Novel EGFR-targeting Therapy April 16, 2018
